Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

R Kanesvaran; C Porta; A Wong; T Powles; Q S Ng; M Schmidinger; D Ye; H Malhotra; Y Miura; J L Lee; F L T Chong; Y-S Pu; C-C Yen; M Saad; H J Lee; H Kitamura; G S Bhattacharyya; G Curigliano; E Poon; S P Choo; S Peters; E Lim; T Yoshino; G Pentheroudakis

doi:10.1016/j.esmoop.2021.100304

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

ESMO Open. 2021 Dec;6(6):100304. doi: 10.1016/j.esmoop.2021.100304. Epub 2021 Dec 1.

Authors

R Kanesvaran¹, C Porta², A Wong³, T Powles⁴, Q S Ng⁵, M Schmidinger⁶, D Ye⁷, H Malhotra⁸, Y Miura⁹, J L Lee¹⁰, F L T Chong¹¹, Y-S Pu¹², C-C Yen¹³, M Saad¹⁴, H J Lee¹⁵, H Kitamura¹⁶, G S Bhattacharyya¹⁷, G Curigliano¹⁸, E Poon⁵, S P Choo¹⁹, S Peters²⁰, E Lim⁵, T Yoshino²¹, G Pentheroudakis²²

Affiliations

¹ Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. Electronic address: ravindran.kanesvaran@singhealth.com.sg.
² Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro' and Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy.
³ Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.
⁴ Barts Cancer Institute, Queen Mary University, London, UK.
⁵ Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
⁶ Department of Urology I, and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
⁷ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
⁸ Department of Medical Oncology, Sri Ram Cancer Center, Mahatma Gandhi Medical College Hospital, Mahatma Gandhi University of Medical Sciences & Technology, Jaipur, India.
⁹ Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
¹⁰ Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
¹¹ Department of Radiotherapy and Oncology, Sabah Women and Children's Hospital, Kota Kinabalu, Sabah, Malaysia.
¹² Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
¹³ Division of Clinical Research, Department of Medical Research and Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan.
¹⁴ Department of Clinical Oncology, University of Malaya Medical Centre, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
¹⁵ Department of Medical Oncology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea.
¹⁶ Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan.
¹⁷ Salt Lake City Medical Center, Kolkata, India.
¹⁸ Istituto Europeo di Oncologia, IRCCS and University of Milano, Milan, Italy.
¹⁹ Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; Medical Oncology, Curie Oncology, Singapore, Singapore.
²⁰ Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
²¹ Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
²² ESMO, Lugano, Switzerland.

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of renal cell carcinoma was published in 2019 with an update planned for 2021. It was therefore decided by both the ESMO and the Singapore Society of Oncology (SSO) to convene a special, virtual guidelines meeting in May 2021 to adapt the ESMO 2019 guidelines to take into account the ethnic differences associated with the treatment of renal cell carcinomas in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with renal cell carcinoma representing the oncological societies of China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter were discussed when appropriate.

Keywords: ESMO; Pan-Asian; guidelines; kidney cancer; renal cell carcinoma treatment.

Publication types

Practice Guideline
Research Support, Non-U.S. Gov't

MeSH terms

Asia
Carcinoma, Renal Cell* / diagnosis
Carcinoma, Renal Cell* / therapy
Follow-Up Studies
Humans
Kidney Neoplasms* / diagnosis
Kidney Neoplasms* / therapy
Medical Oncology